Our Blog

A Certificate of Analysis (COA) is the single most important document that comes with a research peptide order, yet it's also one of the most overlooked. Knowing how to read one — and what to look for — turns an unfamiliar lab report into a clear signal of quality and identity. Here's a practical breakdown of what every COA should tell you.

Reconstituting a lyophilized peptide correctly is one of the most important steps in any research protocol. Use too much or too little bacteriostatic water, and your concentration math (and your results) can be thrown off before you even start. Here's a clear walkthrough of the process our research team follows.

Relocating for a conference, shipping samples between labs, or just moving vials from the freezer to the bench: every step outside cold storage puts peptide integrity at risk. Here's what our research team looks at when planning safe transport for temperature-sensitive compounds.

This week's reporting on compounded GLP-1 products raises a question that goes beyond weight-loss injections: how do you know a compounded peptide is chemically what it claims to be? Stanford Medicine clinicians and independent lab analyses are documenting real gaps — unapproved salt forms, undisclosed additives, and even newly formed molecules that don't exist in the approved drug. Here's what the research actually found, and why verified sourcing is the real answer.

While everyone's been focused on which peptides made this week's FDA advisory vote, a quieter story has been unfolding alongside it: the agency's own scientists recommended against every peptide under review, and now patient safety groups are formally warning that the panel's decision came without the evidence needed to justify it. Here's what ECRI, ISMP, and the Partnership for Safe Medicines actually said, and what it means for anyone buying peptides today.

While everyone's been watching the FDA's advisory committee vote, a new Washington Post investigation points to a bigger, quieter risk: the medspas and wellness clinics actually injecting peptides into consumers face less regulatory oversight than your neighborhood restaurant. Here's what the investigation found, why the gap exists, and what it means for anyone buying peptides today.

For months, social media has insisted that Robert F. Kennedy Jr. already "legalized" a wave of popular research peptides. This week's FDA advisory committee vote added fuel to that story, but the actual paper trail tells a more complicated tale. Here's what's really changed, what's still just talk, and what it means if you're buying peptides today.

This week's FDA Pharmacy Compounding Advisory Committee meeting ended with six peptides recommended for the agency's 503A Bulk Drug Substances List and one turned away. The vote made headlines, but the fine print matters more than the tally. Here is what the committee actually decided, what it does not decide, and why sourcing still matters no matter how the FDA rules.

An FDA advisory panel's split vote on peptide compounding sent Hims & Hers Health shares swinging Thursday, as Wall Street analysts weighed a potential multi-billion dollar telehealth opportunity against lingering safety concerns raised by the agency's own scientists.

Politico's reporting on this week's FDA advisory vote reveals a story bigger than which peptides made the list. It shows a panel reshaped by new appointees, FDA scientists warning they have no guardrails left to apply, and a lobbying fight that now moves to Secretary Robert F. Kennedy Jr.'s desk.

A two-day FDA advisory hearing wrapped up July 24, 2026 with a split decision: six peptides, including BPC-157 and TB-500, were recommended for a pharmacy compounding list, while a seventh, emideltide, was turned away over thin safety data.

A 2026 market-news look at this week's FDA Pharmacy Compounding Advisory Committee vote on BPC-157, TB-500, KPV, and MOTS-c, the additional peptides up for a vote today, and what it could mean for the research peptide supply chain.

A 2026 market-news look at Eli Lilly's newest Phase 3 results for retatrutide, the triple GLP-1/GIP/glucagon peptide now headed toward an FDA biologics application, and what its cardiometabolic data could mean for the next wave of peptide-based obesity research.

A 2026 market-news look at Ascletis Pharma's ASC36_35 fixed-dose peptide combination, its preclinical weight-loss data against the eloralintide/tirzepatide combo, and what once-monthly amylin-GLP-1/GIP co-formulations could mean for the next generation of peptide-based obesity research.

A 2026 market-news look at the FDA's newly expanded Pharmacy Compounding Advisory Committee panel and a fresh national poll on legal peptide access, ahead of this week's vote on seven research compounds, and why verified sourcing matters no matter how the vote goes.

A new Bloomberg investigation, citing blockchain analytics firm Chainalysis, reports that gray-market peptide vendors collected $32 million in cryptocurrency during the first quarter of 2026 alone, a 700% jump from a year earlier. The findings point to a fast-growing shadow economy built around unverified overseas suppliers who accept only Bitcoin because banks and card networks won't process payments for compounds marketed as research chemicals not intended for human use. Here's what the data shows, why buyers are turning to crypto, and why verified, third-party-tested sourcing remains the safer path for legitimate research.

Researchers at the University of Bonn and the Research Center Borstel, Leibniz Lung Center have identified a previously unknown way a synthetic peptide can quiet an overactive immune response. Published in Advanced Science, the study shows that the membrane-active peptide Pep19-2.5 binds directly to human immune cell membranes and blocks activation of the NLRP3 inflammasome, the molecular switch behind chronic airway inflammation in allergic asthma. The findings point to a new pharmacological strategy for regulating inflammation and add to growing research into peptides as precision tools for immune modulation.

A new pilot study from the University of Connecticut, published in Frontiers in Nutrition, found that four weeks of collagen peptide supplementation improved bone-formation biomarkers and reduced inflammation in female runners. The research adds to growing evidence that collagen peptides, long known for skin and joint benefits, may also play a protective role in bone remodeling for a population historically understudied in this area.

A 2026 market-news look at a new Sermo physician survey showing rising peptide misinformation and self-prescribing among US patients, and why documented, third-party-verified sourcing matters more than ever for research use.

A 2026 market-news look at Samsung Biologics' $2 billion acquisition of PolyPeptide Group, the largest M&A in Korean pharma and biotech history, and what the deal signals about surging industrial demand for peptide manufacturing and verified purity in research supply chains.

A 2026 market-news look at NOLA.com's deep dive into the peptide craze — from GLP-1 breakthroughs to gray-market self-injection — and why physicians say sourcing and quality control matter more than the hype.

A 2026 market-news look at why endocrinologists are urging caution on the peptide supplement boom, what the science actually supports, and why verified sourcing matters more than ever for anyone working with research peptides.

A 2026 market-news look at the American Pharmacists Association's formal comments to the FDA ahead of this month's Pharmacy Compounding Advisory Committee meeting, why the group is warning about black and gray market peptides, and what verified sourcing means for research labs.

A 2026 research-news look at a Peking University-led peptide vaccine that trained the immune system to neutralize PCSK9, lowering LDL cholesterol in mouse models, and what an active vaccine approach could mean for the future of peptide-based cardiovascular research.

A 2026 market-news look at Merck's newly FDA-approved LIPFENDRA (enlicitide), the first once-daily oral PCSK9 inhibitor, and what its macrocyclic peptide design means for the future of peptide drug research and sourcing.

A 2026 research-news look at a newly discovered natural peptide aptamer that switches between two unrelated protein targets depending on the surrounding metal ion, and what the finding means for future protein-recognition and biosensor research.

A 2026 market-news look at the newly launched global Phase II trial of CY-101, a synthetic peptide immunotherapy for adrenocortical carcinoma, and what growing clinical validation of peptide-based immunotherapy means for the research community.

A 2026 market-news look at the FDA's April 23 removal of twelve peptides, including BPC-157, TB-500, GHK-Cu, MOTS-c, Epitalon, Semax, and KPV, from its Category 2 restricted-compounding list, and why the shift doesn't change the purity standards research labs should demand.

Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone widely used in receptor-binding and pigmentation-pathway research. This guide covers its research background, mechanism of interest, and purity standards for laboratory use.

ALCAR (Acetyl-L-Carnitine) is a widely studied acetylated amino acid derivative used in mitochondrial and neurocognitive research. This guide covers its research background, mechanism of interest, and purity standards for laboratory use.

A cyclized Cecropin A analog called OMN6 wins ~€8M in EU funding and enters Phase IIa trials targeting carbapenem-resistant Acinetobacter baumannii pneumonia.

A new npj Microgravity study scores 26 peptide-based medications for feasibility of recombinant in-situ production during multi-year space missions.

A new hybrid quantum-classical AI system generated lab-validated peptide binders for understudied HLA immune targets, per a July 2026 preprint from TU Denmark and ORCA Computing.

Penn and CUHK researchers unveil TD3B, an AI framework that designs peptides predicted to activate or block GPCR targets, advancing peptide research and drug discovery tools.

A new JAMA Viewpoint says injectable peptides now sit in a regulatory grey zone. Here's what it means for research sourcing, purity, and compliance.

The FDA's Pharmacy Compounding Advisory Committee meets July 23–24, 2026 to weigh seven peptides for the 503A Bulks List. Here's what it means for research.

The peptide therapeutics market is experiencing powerful momentum in 2026. According to Grand View Research, the global market stood at approximately $140.9 billion in 2025 and is expected to reach $164.0 billion in 2026, on track to hit $294.6 billion by 2033 at a compound annual growth rate (CAGR) of 8.7%.

A 2026 market-news look at why Thymosin Alpha-1 is drawing fresh research interest for immune health and healthy aging, and what the current evidence does and doesn't support.

A 2026 market-news look at KPV, the alpha-MSH-derived tripeptide included in the FDA's upcoming July 23-24 Pharmacy Compounding Advisory Committee review, and what the research says about its proposed anti-inflammatory mechanisms.

A 2026 market-news look at why self-directed peptide use is climbing, what clinicians and major outlets are warning about unsupervised dosing, and how researchers can reduce risk through verified sourcing and rigorous protocols.

A 2026 market-news look at why peptides have become the year's defining longevity and biohacking trend, what physicians are warning about DIY use, and why verified sourcing matters more than ever.

A 2026 market-news roundup of the peer-reviewed and preclinical research behind BPC-157, its current regulatory status, and the purity standards that keep tissue-repair research reproducible.

A 2026 market-news look at how fast the research peptide industry is growing, and why the widening gap between third-party HPLC-verified compounds and unverified gray-market imports matters more than the growth numbers themselves.

A 2026 market-news briefing on the FDA's Pharmacy Compounding Advisory Committee review of seven bulk peptides — and why the outcome matters for research-grade sourcing standards.

A 2026 research-use-only deep dive into MOTS-c, SS-31, and the mitochondrial peptides driving longevity and cellular-energy research, plus the handling and third-party purity standards that keep results reproducible.

A 2026 research-use-only comparison of the triple agonist Retatrutide and the dual agonist Tirzepatide: receptor profiles, how each is studied in metabolic models, and the purity standards that support reproducible results.

A 2026 research-use-only overview of how BPC-157 is studied across tissue-repair models, its proposed mechanisms, and the purity standards that support reproducible results.

Epithalon (also spelled epitalon) is a synthetic tetrapeptide studied for its proposed effects on telomerase activity and cellular aging. This guide explains what the peptide is, how it's investigated in longevity and chronobiology research models, and the purity and storage standards every lab should verify. For laboratory research use only.

GHK-Cu is one of the most studied copper peptides in regenerative research. This guide breaks down its role in collagen synthesis, skin remodeling, and wound-healing pathways, plus reconstitution, storage, and purity standards every researcher should verify. For laboratory research use only.

Research peptides are short-chain amino acid sequences designed for scientific investigation. Unlike pharmaceutical drugs, they are produced for laboratory research only and must not be used on humans or animals. Understanding their purity standards, storage requirements, and procurement sources is essential for credible research outcomes.

NAD+ and NMN are two of the most studied molecules in longevity and cellular-energy research, but they play different roles in the NAD+ pathway. This guide compares their mechanisms, research applications, and stability so labs can choose the right compound and verify purity before study. For laboratory research use only.

From BPC-157 and TB-500 to Epithalon, GHK-Cu, and MOTS-c, longevity peptides are among the fastest-growing areas of preclinical research. This 2026 guide ranks five of the most studied longevity research peptides, what each is investigated for, and the purity standards labs should verify. For laboratory research use only.

BPC-157 and TB-500 are two of the most studied peptides in tissue-repair and recovery research, and they are frequently investigated together as a complementary stack. This guide explains how each peptide works, why researchers pair them, and the purity and storage standards every protocol should verify. For laboratory research use only.

Retatrutide (Reta) is a triple GLP-1/GIP/glucagon receptor agonist showing superior metabolic outcomes in preclinical research versus dual-agonist semaglutide. This deep-dive compares receptor binding profiles, research findings, dosing considerations, and where each peptide excels — helping researchers choose the right compound for their protocols.